NCT02798861View on ClinicalTrials.gov

Controlled Attenuation Parameter (CAP) in Liver Allografts

CompletedOBSERVATIONAL
Enrollment

160

Participants

Timeline

Start Date

September 7, 2016

Primary Completion Date

June 1, 2019

Study Completion Date

June 1, 2019

Conditions
Liver TransplantLiver SteatosisLiver DiseasePrimary Non-functionEarly Allograft Dysfunction
Interventions
DEVICE

Fibroscan 402/530

Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.

Trial Locations (3)

55905

Mayo Clinic, Rochester

72205

University of Arkansas for Medical Sciences, Little Rock

94305

Stanford University, Stanford

All Listed Sponsors
lead

Andres Duarte-Rojo

OTHER

NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts | Biotech Hunter | Biotech Hunter